Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CM-272 是一种可逆底物竞争性双重G9a/DNA 甲基转移酶选择性抑制剂,具有抗肿瘤活性。它抑制细胞增殖并促进细胞凋亡,诱导干扰素刺激的基因和免疫原性细胞死亡。它抑制G9a、DNMT1、DNMT3A、DNMT3B 和GLP,IC50分别为 8 nM、382 nM、85 nM、1200 nM 和 2 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 658 | 现货 | ||
5 mg | ¥ 1,550 | 现货 | ||
10 mg | ¥ 2,730 | 现货 | ||
25 mg | ¥ 4,350 | 现货 | ||
50 mg | ¥ 6,320 | 现货 | ||
100 mg | ¥ 8,660 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,630 | 现货 |
产品描述 | CM-272 is a dual G9a/DNA methyltransferases (DNMTs) inhibitor. |
靶点活性 | DNMT3B:1200 nM (IC50), G9a:8 nM, GLP:2 nM, DNMT3A:85 nM, DNMT1:382 nM |
体外活性 | CM-272, inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death. CM-272 significantly prolongs survival of AML, ALL and DLBCL xenogeneic models. |
体内活性 | CM-272 (2.5 mg/kg; intravenous injection; daily; for 28 days; female Rag2?/?γc?/? mice) treatment significantly prolongs survival of CEMO-1 cells xenogeneic models.Induced a statistically significant increase in overall survival (OS) in mice. |
细胞实验 | Cell Line:CEMO-1, MV4-11 and OCI-Ly10 cell lines. Concentration:125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells). Incubation Time:12 hours, 24 hours, 48 hours and 72?hours |
动物实验 | CM-272 (2.5 mg/kg; intravenous injection; daily; for 28 days; female Rag2?/?γc?/? mice) treatment significantly prolongs survival of CEMO-1 cells xenogeneic models. Animal Model:Female BALB/Ca-Rag2?/?γc?/? mice (6–8-week-old) with CEMO-1 cells. Dosage:2.5 mg/kg. Administration:Intravenous injection; daily; for 28 days |
分子量 | 478.63 |
分子式 | C28H38N4O3 |
CAS No. | 1846570-31-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 96 mg/mL (200.57 mM)
Ethanol: 96 mg/mL (200.57 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.0893 mL | 10.4465 mL | 20.893 mL | 52.2324 mL |
5 mM | 0.4179 mL | 2.0893 mL | 4.1786 mL | 10.4465 mL | |
10 mM | 0.2089 mL | 1.0446 mL | 2.0893 mL | 5.2232 mL | |
20 mM | 0.1045 mL | 0.5223 mL | 1.0446 mL | 2.6116 mL | |
50 mM | 0.0418 mL | 0.2089 mL | 0.4179 mL | 1.0446 mL | |
100 mM | 0.0209 mL | 0.1045 mL | 0.2089 mL | 0.5223 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CM-272 1846570-31-7 Apoptosis Chromatin/Epigenetic DNA Methyltransferase Histone Methyltransferase DNMT1 anti-tumour DNMTs immunogenic DNA MTases DNMT3A G9a H3K9me2 Inhibitor epigenetics GLP inhibit substrate-competitive DNMT3B CM272 CM 272 inhibitor